Michael A. Poch, MD

Where You Are:

Michael A. Poch, MD



          •  Urology

          •  Rosewell Park Cancer Institute - Urologic Oncology

          •  Rhode Island Hospital, Brown University - General Surgery and Urology

          •  Alpert Medical School at Brown University - MD

  • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):225-230. Pubmedid: 25544725.

  • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Mar. Pubmedid: 25774005.

  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Jan. Pubmedid: 25552207.

  • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2014 Dec. Pubmedid: 25777366.

  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. J Natl Compr Canc Ne. 2014 Sep;12(9):1211-1219. Pubmedid: 25190691.

  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug;192(2):350-356. Pubmedid: 24530987.

  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul;32(5):619-624. Pubmedid: 24495448.

  • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy?intensity modulated radiation therapy. Radiother Oncol. 2014 Apr;111(1):126-131. Pubmedid: 24746567.

  • Poch MA, Stegemann AP, Rehman S, Sharif MA, Hussain A, Consiglio JD, Wilding GE, Guru KA. Short-term patient reported health-related quality of life (HRQL) outcomes after robot-assisted radical cystectomy (RARC). BJU Int. 2014 Feb;113(2):260-265. Pubmedid: 23773798.

  • Poch MA, Mehedint D, Green DJ, Payne-Ondracek R, Fontham ET, Bensen JT, Attwood K, Wilding GE, Guru KA, Underwood W, Mohler JL, Heemers HV. The association between calcium channel blocker use and prostate cancer outcome. Prostate. 2013 Jun;73(8):865-872. Pubmedid: 23280547.

  • Rao AR, Stegemann AP, Rehman S, Poch MA, Green D, Guru KA. Status of Robot-Assisted Radical Cystectomy (RARC) in 2012. Indian J Surg Oncol. 2013 Jun;3(2):85-90. Pubmedid: 23730095. Pmcid: PMC3392479.

  • Poch MA, Raza J, Nyquist J, Guru KA. Tips and tricks to robot-assisted radical cystectomy and intracorporeal diversion. Curr Opin Urol. 2013 Jan;23(1):65-71. Pubmedid: 23202288.

  • Poch MA, Stegemann A, Chandrasekhar R, Hayn M, Wilding G, Guru KA. Does body mass index impact the performance of robot-assisted intracorporeal ileal conduit?. J Endourol. 2012 Jul;26(7):857-860. Pubmedid: 22332715.

Dr. Poch's research interests include health-related quality of life outcomes after oncologic surgery. He current research projects including assessment of patient centered treatment preferences for urinary diversion after bladder removal surgery. In addition is involved in active enrollment of patients onto Moffitt Sponsored clinical trials.


His clinical interests include bladder, kidney, testis and prostate cancer with an emphasis on surgical robotics and minimally invasive surgery. He is a reviewer for numerous professional journals, and is published in many peer-reviewed journals and has authored many book chapters on urologic oncology and robotics. He is speaker at national and international urology conferences.


A native of Connecticut, Dr. Poch entered Brown University as an undergraduate in the Program of Liberal Medical Education. He graduated with a BA in Biology from Brown University and went on to complete medical school there at the Brown Medical School. He stayed in Providence at Rhode Island Hospital/Brown University for his Urology residency before traveling to Buffalo to complete a Society for Urologic Oncology fellowship at Roswell Park Cancer Institute. He has been an Assistant Member at Moffitt Cancer Center since 2012.


Dr. Poch is an Assistant Professor at the University of South Florida, Morsani College of Medicine and is involved in medical student education where he provides mentorship and clinical education for first and second year medical students.


His hobbies include cycling, snowboarding, international travel and cooking.

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions